![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CW Stevens and TL Yaksh
The intrathecal delivery of dynorphin A (1-17) and (1-13) induces, with rapid onset, a severe motor dysfunction characterized by flaccid extension of the hindlimbs and complete loss of muscle tone. This motor effect does not appear to be mediated via opiate receptors as high doses of naloxone neither block nor reverse motor dysfunction, and it is produced by dynorphin A fragments inactive at opiate receptors. At doses just below those which produce motor dysfunction, dynorphin A has no effect on nociceptive responses in the hot-plate, tail-flick and writhing tests. The selective, kappa opiate agonist, U50488H, produces a significant, dose-dependent inhibition of writhing, which is antagonized by pretreatment with naloxone, but has no effect on hot- plate and tail-flick latency. The kappa agent U50488H does not produce motor dysfunction with doses as high as 300 nmol/rat. It appears that the potent kappa opiate activity exhibited by dynorphin A in vitro may not reflect in vivo effects of dynorphin after intrathecal administration.
This article has been cited by other articles:
|
|
 |
|
  T. Yamamoto, K. Shono, and S. Tanabe Buprenorphine Activates {micro} and Opioid Receptor Like-1 Receptors Simultaneously, but the Analgesic Effect Is Mainly Mediated by {micro} Receptor Activation in the Rat Formalin Test J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 206 - 213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kroin, A. Buvanendran, S. K.S. Nagalla, and K. J. Tuman Postoperative pain and analgesic responses are similar in male and female Sprague-Dawley rats: [Les reactions a la douleur postoperatoire et aux analgesiques sont similaires chez les rats et les rates Sprague-Dawley] Can J Anesth, November 1, 2003; 50(9): 904 - 908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Sluka, J. J. Rohlwing, R. A. Bussey, S. A. Eikenberry, and J. M. Wilken Chronic Muscle Pain Induced by Repeated Acid Injection Is Reversed by Spinally Administered {micro}- and delta -, but Not kappa -, Opioid Receptor Agonists J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1146 - 1150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Laughlin, A. A. Larson, and G. L. Wilcox Mechanisms of Induction of Persistent Nociception by Dynorphin J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 6 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lai, M. H. Ossipov, T. W. Vanderah, T. P. Malan Jr., and F. Porreca Neuropathic Pain: The Paradox of Dynorphin Mol. Interv., August 1, 2001; 1(3): 160 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Kroin, R. J. McCarthy, N. Von Roenn, B. Schwab, K. J. Tuman, and A. D. Ivankovich Magnesium Sulfate Potentiates Morphine Antinociception at the Spinal Level Anesth. Analg., April 1, 2000; 90(4): 913 - 917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Burton and G. F. Gebhart Effects of Kappa-Opioid Receptor Agonists on Responses to Colorectal Distension in Rats with and without Acute Colonic Inflammation J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 707 - 715. [Abstract] [Full Text]
|
|
|
|
|
|
V. K. Shukla, J. A. Prasad, and S. Lemaire Nonopioid Motor Effects of Dynorphin A and Related Peptides: Structure Dependence and Role of the N-Methyl-D-aspartate Receptor J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 604 - 610. [Abstract] [Full Text]
|
|
|
|
|
|
M. K. Greenwald, M. L. Stitzer, and K. A. Haberny J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1154 - 1163. [Abstract] [Full Text]
|
|
|
|
|
|
G. Pugh Jr., D. J. Mason Jr., V. Combs, and S. P. Welch Involvement of Dynorphin B in the Antinociceptive Effects of the Cannabinoid CP55,940 in the Spinal Cord J. Pharmacol. Exp. Ther., May 1, 1997; 281(2): 730 - 737. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
